In this episode, our CEO Dr. Antonella Santuccione Chadha had the opportunity to speak about a topic that is both deeply personal and scientifically urgent: the gender differences in mental and neurological disorders affecting women.

While women live longer than men, they spend approximately 25% more of their lives with health impairments. Psychiatric and neurological conditions disproportionately affect women—depression, anxiety, eating disorders, and migraines are significantly more prevalent. ADHD is often diagnosed late, and two-thirds of those living with Alzheimer’s dementia are women. These patterns are not coincidental; they reflect a complex interplay of biology, hormones, and systemic gaps in research and care.

From puberty to menopause, women experience heightened vulnerability to brain-related disorders. Yet, gender-specific research remains underfunded and underrepresented in clinical trials. This must change.

Dr. Santuccione Chadha advocates for a future where sex and gender differences are not overlooked but embraced as essential to progress. In her recent conversation with Dr. med. Rosilla Bachmann Heinzer, they explored:

➡️ Why gender-specific preclinical and clinical research is critical

➡️ How these insights can transform pharmacotherapy and care

➡️ The importance of investing in Women’s Brain Capital—a concept that recognizes and protects women’s cognitive and emotional performance as a societal asset

Listen Now

 

Leave a Reply

Your email address will not be published. Required fields are marked *

We are here to transform medicine and healthcare towards precision medicine. Right now, there is a critical need for your support. Donate today and help us continue to study Sex and Gender differences impacting brain and mental diseases.

Health begins with human beings, individuals – men and women are different when it comes to brain and mental disease frequency, severity, symptomatology, risk factors and even response to treatments. Thanks to the gifts from supporters like you the scientific community is starting to take note. We have shown the world that in diseases like Alzheimer’s for instance, disease progression is faster in women than men and women show different levels of biomarkers.

Our goal is to clearly identify such differences in diseases, diagnostic, and treatments, as well as novel technologies, and leverage them for better solutions. We ask for better clinical outcomes, better care, and innovative artificial intelligence (AI)-based solutions. Sex and gender differences are the first steps towards precision medicine, which acknowledges the specific needs of each patient. Our ultimate ambition is the realisation of the Research Institute for Sex and Gender Precision Medicine.